Featured Articles

  1. AI In A Time Of Uncertainty: Key Strategies To Enable Flexibility 3/4/2025

    Given the near-constant technological advancements in AI, potential AI policy updates, and regulatory changes, flexible AI systems are necessary for life science organizations to keep pace with change.

  2. A CEO With A General Counsel's Perspective 2/28/2025

    LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous perspective on the CEO role.

  3. Interchangeability In Leadership: A Career Built On Versatility 2/27/2025

    Adaptability serves as the foundation for lasting career success, shaping leaders who can thrive in an ever-changing business landscape, explains Mary Beth Sandin.

  4. An Updated View of The Federal Segment: DHA Formulary Management 2/25/2025

    Part two of a three-part series aimed at helping drug and device manufacturers better navigate and understand the Veterans Affairs and Department of Defense health systems.

  5. FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance 2/21/2025

    Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order. That doesn't mean biopharmaceutical companies can backslide on compliance in global markets.

  6. A Guide To Successful Product Launches For Small And Midsized Biotechs 2/19/2025

    Abhijit Naravane, a partner at PA Consulting, outlines strategies to help biopharma operations leaders successfully navigate the complexities of a product launch.

     

  7. Tax Planning For Life Sciences Amid Shifting Policies 2/11/2025

    Tax policy shifts can directly affect corporate structure decisions, overall business strategy, and the ability to allocate resources effectively. In 2025, staying ahead of these changes will be vital, writes life sciences tax expert Richard Weiner.

  8. The Spark Of Change In Healthcare's 2024 Investment Ecosystem 2/6/2025

    Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven strategies, have set the healthcare and biotech industries on a positive trajectory for 2025, writes Joseph Pategou.

  9. How Pharma Can Best Manage Third-Party Risk 2/4/2025

    Experts at Crowe Life Sciences offer tips for effectively managing risk associated with third parties such as clinics, retail pharmacies, health information system providers, and independent research organizations.

  10. Rethinking Global-To-Local Pricing And Market Access For Pharmaceuticals 1/31/2025

    Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access strategies, from core markets to the local affiliate level in non-core markets.